Avondale Partners Downgrades Diplomat Pharmacy (DPLO) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Leerink Partners Downgrades Diplomat Pharmacy (DPLO) to Market Perform
November 3, 2016 6:59 AM EDTLeerink Partners downgraded Diplomat Pharmacy (NYSE: DPLO) from Outperform to Market Perform with a price target of $18.00 (from $35.00).
Analyst David Larsen commented, "Yesterday afternoon DPLO reduced its outlook for 2016 and provided a preliminary outlook for 2017 that was well below expectations. As a... More
Diplomat Pharmacy (DPLO) Misses Q3 EPS by 3c, Offers Guidance
November 2, 2016 5:16 PM EDTDiplomat Pharmacy (NYSE: DPLO) reported Q3 EPS of $0.21, $0.03 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $1.18 billion versus the consensus estimate of $1.26 billion.
GUIDANCE:
Diplomat Pharmacy sees FY2016 EPS of $0.83-$0.87, versus the consensus of... More
